drugset / Trial / NCT00914290

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis

NCT00914290

Phase 2 Completed 23 enrolled Impax Laboratories, LLC
RandomizedCrossoverDouble-blindTreatment

Summary

To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).

Timeline

Start
2009-04
Primary completion
2010-01
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 5 mg
Subject IPX056 Unknown 10 mg

Indications